Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
Apply
N-803, Irinotecan, Temozolomide, Hu14-18K322A, GM-CSF
A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step